RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome

By sjmartinez • April 20, 2023

Nishio M, Paz-Ares L, Reck M, Nakagawa K, Garon EB, Popat S, Ceccarelli M, Graham HT, Visseren-Grul C, Novello S. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome. Clin Lung Cancer. 2023 Mar 21:S1525-7304(23)00046-3. doi: 10.1016/j.cllc.2023.02.010. Epub ahead of print. PMID: 37076395.

Tags: EGFR-TKI, Hematology/Oncology, Non-small cell lung cancer, Publications, ramucirumab, TP53, VEGF inhibition

Longitudinal Study on the Influence of Physical Activity in Managing Fatigue in Patients With Colorectal Cancer

Liu L, Kazemian E, Loroña NC, Shirazipour C, Gong J, Crowder SL, Nguyen N, Damerell V, Mooney K, Playdon MC, Ulrich CM, Li CI, Shibata[...]

Polycyclic aromatic hydrocarbons, gut microbiome composition, impulsivity, and attention covary in a human cohort

Hammer AJ, Kasschau KD, Davis Ii EW, Hoffman P, Johnson-Camacho K, Alexiev A, Anderson K, Shannon J, Marriott LK, Sharpton TJ. Polycyclic aromatic hydrocarbons, gut[...]

Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study

Cluzeau T, Borate U, McMahon C, Fenaux P, Heiblig M, Peterlin P, Ball B, Chantepie S, Eghtedar A, Kambhampati S, Solh M, Torregrosa-Diaz J, Braun[...]